Medical Director Cardiovascular Jobs (NOW HIRING)

Position:Medical Director, Cardiovascular

Location: Bedford, MA

Job Id:112995

# of Openings:1

MannKind

MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.
At MannKind, our employees are our greatest asset. We foster a close-knit, collaborative culture where every team member plays a vital role in our mission. We are proud to champion a rich blend of backgrounds, perspectives, and working styles as we work together to improve health outcomes and change lives.

Position Summary

The Medical Director, Cardiovascular is a respected medical leader and subject matter expert in heart failure and fluid overload who influences the advancement of innovative therapies through strategic clinical guidance and scientific leadership. Partnering closely with Clinical Development, Medical Affairs, and Commercial teams, this role provides expert input on development-stage and postmarketing programs, helping shape evidence generation and medical strategy. The Medical Director serves as a trusted scientific voice for the organization, ensuring clinical integrity, meaningful stakeholder engagement, and alignment with the company’s vision for improving patient outcomes.

The Medical Director provides strategic leadership for Translational Medicine, Clinical Development, Clinical Operations, Biostatistics/Data Management, Medical Affairs, Drug Safety / Pharmacovigilance, and Regulatory Affairs to advance integrated development and lifecycle planning. The Medical Director also provides cross‑functional scientific leadership and medical expertise to commercial and market access counterparts.

Key Responsibilities: Therapeutic Area Leadership & Strategy

• Advance clinical programs across Cardiorenal disorders, and associated chronic disease pathways, integrating parenteral and pulmonary drug delivery strategies where relevant.
• Serve as the senior clinical authority for Cardiorenal drug development, representing the therapeutic area across executive, governance, and strategic decision‑making forums.
• Synthesize scientific, clinical, regulatory, and competitive insights to guide pipeline prioritization, shape evidence strategies, and inform long-range portfolio and lifecycle planning.
• (Define and) Partner with the CMO to lead the clinical development strategy for the heart failure portfolio, ensuring alignment with MannKind's scientific platforms, inhaled-therapeutic technologies, and long-term enterprise objectives.

Clinical Study Planning & Design

• Lead the design and planning of Phase 1–4 clinical trials across cardiorenal and related chronic disease indications, including dose selection, patient segmentation, biomarker strategy, and endpoint development.
• Engage internal scientific leaders and external experts across cardiology, nephrology, critical care, and related specialties to refine study rationale, strengthen mechanistic understanding, and optimize development pathways.
• Oversee advisory board strategy and insight generation to integrate cross-disciplinary perspectives and ensure study designs reflect real-world clinical practice and unmet need.
• Ensure clinical protocols meet the highest standards of scientific integrity, operational feasibility, and regulatory alignment, supporting efficient execution and high-quality evidence generation.

Clinical Study Execution & Oversight

• Oversee the execution of all Cardiorenal clinical programs, directing cross-functional interfaces to ensure robust, efficient, and high-quality delivery of evidence across early-and late-stage development.
• Biostatistics & Data Management – Partner closely to ensure data integrity, statistical rigor, and high-quality analyses that support regulatory submissions and scientific decision-making.
• Safety / Pharmacovigilance – Define safety strategy, oversee safety surveillance, interpret emerging safety signals, and ensure comprehensive risk‑benefit assessments throughout development.
• Translational Medicine & Clinical Pharmacology – Guide biomarker strategy, PK/PD modeling, and mechanistic endpoint selection to strengthen scientific understanding and accelerate development.
• Clinical Operations – Provide input into CRO and vendor oversight, operational planning, site engagement, and execution of global clinical studies.
• Ensure all studies adhere to FDA, EMA, and global regulatory requirements, including GCP, ethical standards, and inspection readiness.
• Maintain accountability for medical monitoring, serving directly as the medical monitor or by providing leadership and oversight to delegated medical monitors.

Regulatory Leadership & Scientific Communication

• Lead regulatory strategy and submission development for the Cardiorenal portfolio, including INDs, NDAs/BLAs, briefing documents, clinical study reports, and responses to regulatory agencies.
• Represent the therapeutic area in FDA, EMA, and global regulatory interactions, ensuring teams are fully prepared for meetings, advisory committees, inspections, and cross‑agency engagements.
• Oversee the development, review, and approval of all key scientific and regulatory documents, including clinical protocols, CSRs, investigator brochures, and internal or external scientific communications.

Medical Affairs Collaboration

• Provide content leadership to Medical Affairs to shape scientific platforms, disease‑area lexicons, and evidence strategies across cardiorenal conditions.
• Ensure alignment between clinical development strategy and field‑based medical strategy, driving consistent non‑promotional scientific messaging across medical/clinical and payor audiences.
• Support publication planning and scientific communication, ensuring clarity, accuracy, and cohesion across the evolving evidence base.

Data Analysis, Interpretation & Strategic Insight Integration

• Guide the analysis, interpretation, and communication of clinical data across cardiology, nephrology, and heart failure expert audiences, ensuring scientific rigor and strategic clarity.
• Synthesize emerging scientific, clinical, and competitive insights to refine development strategy, inform evidence‑generation plans, and adapt to evolving scientific trends.
• Provide strategic recommendations to executive leadership based on trial learnings, external landscape shifts, and evolving therapeutic opportunities.

Cross‑Functional Leadership & Enterprise Influence

• Partner with Commercial, Market Access, and Business Development to ensure clinical evidence supports market needs, access strategies, and differentiated product positioning.
• Lead or support diligence activities for potential in‑licensing, collaborations, or partnerships across cardiorenal and related systemic disease areas.
• Serve as a key contributor within enterprise governance, providing therapeutic area expertise to inform pipeline investments, milestone decisions, and portfolio prioritization.
• Responsible for Cardiorenal TA medical/scientific resourcing and budget planning in partnership with SMLT Leaders.

People Leadership & Organizational Development

• Serve on the Senior Medical Leadership Team and contribute to overall collective leadership for all medical issues across all Therapy Areas and Operational Functions, including but not limited to the Cardiorenal TA.
• Mentor medical colleagues and cultivate an organizational culture grounded in scientific excellence, accountability, transparency, and cross‑functional collaboration.
• Drive workforce planning, talent development, succession planning, and competency building to ensure the organization has the capabilities required for future growth.

Education and Experience Qualifications: Education:

• M.D. required, with clinical experience in medical practice preferred, ideally as a cardiologist, critical care physician, or nephrologist. An additional PhD, MPH, or MBA also highly valued.

Experience:

• 5+ years of progressive medical affairs and/or clinical development experience within the pharmaceutical or biotechnology industry.
• Demonstrated expertise in cardiovascular disease (and specific experience in congestive heart failure strongly preferred).
• Track record of designing and executing clinical trials in cardiovascular chronic disease populations (and experience with wearable devices preferred)
• Proven ability to lead and influence cross‑functional teams, collaborate effectively with investigators and scientific leaders, and represent programs in global regulatory interactions.
• Exceptional scientific communication, analytical, and leadership capabilities, with the ability to convey complex clinical concepts to diverse internal and external stakeholders.
• Ability and willingness to travel approximately 20%, primarily domestically, with occasional international travel.

Industry Knowledge

• Deep understanding of clinical development methodologies, including biomarker strategy, pK/pD principles, translational medicine approaches, and regulatory pathways for cardiorenal diseases.
• Knowledge of U.S. (and ex-U.S.) regulatory and clinical research requirements relevant to cardiovascular drug development.
• Demonstrated ability to integrate scientific insights, regulatory expectations, competitive intelligence, and operational considerations into cohesive, forward‑looking development strategies.

With the spread of the coronavirus, many individuals are concerned about access to their medication supply. At this time, MannKind does not anticipate that the supply of its inhalable insulin Afrezza ® (insulin human) Inhalation Powder will be affected by the coronavirus.

We will continue to closely monitor our supply chain for potential impact to the supply of Afrezza. MannKind sources critical raw materials from suppliers in the United States and Europe and we remain in close communication with key suppliers to assure a reliable supply of insulin.

Our US manufacturing facility is fully operational and we are taking a number of steps to prevent any impact to our supplies. Afrezza is still readily available in U.S. pharmacies, and if needed, pharmacies can order additional supplies from wholesalers with expected delivery within 1-2 days. As the global situation evolves, we will continue to take the necessary steps to safeguard the reliable supply of Afrezza.